30 closest matches · ranked by relevance
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) — 9.89; 27.7 Months
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) Rate After 12 Months — 50.24 Percent probability of PFS
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment of Afatinib as First-line Therapy in Advanced Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Mutation — 14.4 Months
Non-Small Cell Lung Cancer
Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 — 0.0 Percentage of participants
Lung Cancer
Primary: Overall Survival (OS) — 22.8 Months
Carcinoma，Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001
NSCLC
Primary: Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) — 7; 6; 4; 5 Participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Lung Cancer
Primary: Body Mass Index (BMI): All Asian Participants — 22.6; 23.1; 26.4 Kilogram per square meter
EGFR Mutation Status in aNSCLC Patients
Primary: Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status — 59.2; 52.0; 77.4; 70.7 Percentage of participants
Non Small Cell Lung Carcinoma
Primary: Objective Response Rate(ORR) — 31.2 Percent of participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Duration of Progression-free Survival — 11.0; 5.5 Months
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-Free Survival (PFS) Time — 11.17; 6.90 Months. — p=0.0002
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.95; 6.83 Months — p=0.0618
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months